Karim Mikhail, Amarin CEO
June 10, 2022 02:51 PM EDTUpdated 04:26 PM
Pharma

UK’s NICE grants ac­cess to Amar­in's cho­les­terol drug amid US staff cuts

Tyler Patchen

News Reporter

The UK’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence, or NICE, on Fri­day agreed to cov­er Amarin’s con­tro­ver­sial cho­les­terol drug Vas­cepa, amidst tur­bu­lence for Amarin …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times